Table 3 The top 25 metabolic pathways distinguishing the high-residential radon exposure group from the low-residential radon exposure group.
Pathways | Total | Hits | Hits compound | P value |
|---|---|---|---|---|
1. SARS-CoV-2 and COVID-19 pathway | 5 | 1 | D-Sphingosine | 0.002 |
2. GDNF signaling | 7 | 1 | D-Sphingosine | 0.003 |
3. Modulation of PI3K-Akt-mTOR signaling by bioactive sphingolipids | 10 | 1 | D-Sphingosine | 0.005 |
4. VEGFR2 mediated cell proliferation | 11 | 1 | D-Sphingosine | 0.005 |
5. Sphingolipid metabolism in senescence | 14 | 1 | D-Sphingosine | 0.007 |
6.Degradation pathway of sphingolipids, including diseases | 14 | 1 | D-Sphingosine | 0.007 |
7. Synthesis of ceramides and 1-deoxyceramides | 23 | 1 | D-Sphingosine | 0.011 |
8. Sphingolipid pathway | 24 | 1 | D-Sphingosine | 0.011 |
9. Extra-nuclear estrogen signaling | 27 | 1 | D-Sphingosine | 0.013 |
10. Sphingolipid metabolism overview | 27 | 1 | D-Sphingosine | 0.013 |
11. Signaling by VEGF | 28 | 1 | D-Sphingosine | 0.013 |
12. VEGFA-VEGFR2 Pathway | 28 | 1 | D-Sphingosine | 0.013 |
13. 10q11.21q11.23 copy number variation syndrome | 30 | 1 | D-Sphingosine | 0.014 |
14. ESR-mediated signaling | 33 | 1 | D-Sphingosine | 0.015 |
15. Metabolism of sphingolipids in ER and Golgi apparatus | 34 | 1 | D-Sphingosine | 0.016 |
16. Glycosphingolipid metabolism | 35 | 1 | D-Sphingosine | 0.016 |
17. Fabry disease | 35 | 1 | D-Sphingosine | 0.016 |
18. Gaucher Disease | 35 | 1 | D-Sphingosine | 0.016 |
19. Globoid Cell Leukodystrophy | 35 | 1 | D-Sphingosine | 0.016 |
20. Krabbe disease | 35 | 1 | D-Sphingosine | 0.016 |
21. Metachromatic Leukodystrophy (MLD) | 35 | 1 | D-Sphingosine | 0.016 |
22. Sphingolipid de novo biosynthesis | 36 | 1 | D-Sphingosine | 0.017 |
23. 16p11.2 proximal deletion syndrome | 39 | 1 | D-Sphingosine | 0.018 |
24. Sphingolipid metabolism: integrated pathway | 49 | 1 | D-Sphingosine | 0.023 |
25. Signaling by Nuclear Receptors | 50 | 1 | D-Sphingosine | 0.023 |
